CVS Pharmacy Inc. and several subsidiaries have agreed to pay $315 million to resolve a Justice Department lawsuit accusing the company of unlawfully dispensing medically unnecessary prescriptions for highly addictive opioids, officials said. The case, filed in Washington, centered on allegations that the pharmacy giant filled massive quantities of opioids and other controlled substances in ways that fueled profits at the expense of public health and safety.
According to News4JAX, the lawsuit, brought in 2024, accused CVS of violating the Controlled Substances Act by filling illegitimate prescriptions for high doses of potent opioids. The Justice Department alleged the company dispensed large quantities of the drugs based on prescriptions from known pill mills — providers that issue prescriptions without a legitimate medical purpose. Many of those prescriptions were billed to and reimbursed by Medicaid and other federal healthcare programs, per the same report.
Staffing and Incentives Under Scrutiny
Investigators alleged that poor staffing levels, combined with performance metrics and incentive compensation policies, pushed CVS pharmacists to fill prescriptions without properly verifying their legitimacy, the article notes. CVS pushed back on that characterization in 2024, saying its pharmacists were held to vague, undefined and changing standards for filling prescription opioids. The company has also said its pharmacists were trained in the safe and appropriate use of all medications and backed by programs designed to support patient decisions.
As part of the resolution, CVS must now implement additional safeguards to ensure opioids and other controlled substances are dispensed only when medically appropriate. The company maintains the settlement includes no admission of liability. CVS said it strongly disagreed with the lawsuit's claims and that the settlement admits no wrongdoing.
Officials Call It a Milestone
Stanley Woodward said the settlement marks a significant milestone in the Justice Department's efforts against the opioid epidemic, according to the reporting. The federal government has pursued accountability from companies alleged to have helped fuel the nation's addiction and overdose crisis, and this case adds to a string of enforcement actions against the pharmacy industry.
CVS has separately pointed to its own enforcement record on the issue. The company says it has blocked more than 1,250 practitioners through an internal program targeting controlled-substance prescribers of potential concern, including nearly 600 who remain licensed by the government, according to a statement posted on CVS Health. The company also said it has cooperated with the Justice Department's investigation for more than four years even as it disputed the allegations.
Part of a Decade of Mounting Settlements
This case lands amid a broader wave of opioid litigation. Drugmakers, wholesalers, pharmacies and other companies have agreed to settlements totaling more than $50 billion with U.S. governments over the past decade, the report states. Most of that money and most of those settlements have gone to state and local governments, with funds intended to address the ongoing crisis.
The federal government has reached opioid-related settlement deals with other major pharmacy chains in the last two years, including Walgreens and Walmart. CVS itself was part of an earlier, larger reckoning: in November 2022, CVS Health Corp., Walgreens Boots Alliance Inc. and Walmart Inc. agreed to pay about $13.8 billion to resolve thousands of state and local lawsuits accusing the chains of mishandling opioid pain medications, according to Reuters.
The opioid crisis has been linked to more than 100,000 deaths in the United States in some years, the AP report notes, though the scale of that toll has shaped years of federal and state enforcement actions against the industry. The $315 million settlement represents the latest chapter in that effort, one that officials frame as part of a continuing push to hold pharmacy chains accountable for how controlled substances reach patients nationwide.
